Joanne Quan Sells 1,822 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $170,047.26. Following the completion of the transaction, the insider owned 12,817 shares in the company, valued at $1,196,210.61. This trade represents a 12.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Joanne Quan also recently made the following trade(s):

• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97.

Mirum Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:MIRM opened at $94.29 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The stock’s 50-day moving average is $77.33 and its 200-day moving average is $70.78. The company has a market cap of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $96.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) EPS. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MIRM. Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after buying an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after buying an additional 1,720 shares in the last quarter. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals in the first quarter valued at $217,000. Finally, Empowered Funds LLC raised its stake in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently commented on MIRM. HC Wainwright reiterated a “buy” rating and set a $102.00 target price (up from $81.00) on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 13th. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Finally, JMP Securities set a $95.00 price target on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.58.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.